2.66

2.31% 0.06

After Hours: 2.64 -0.02 -0.75%

Boundless Bio Inc (BOLD)

Overview News Price History Discussions Forecast

Boundless Bio Inc stock is traded at $2.66, with a volume of 255.08K. It is up +2.31% in the last 24 hours and down -9.52% over the past month. Boundless Bio Inc is a clinical-stage oncology company. It is focused on developing cancer therapeutics that address the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Using its proprietary Spyglass platform, the company identifies targets essential for ecDNA functionality, then designs and develops small-molecule drugs called ecDNA-directed therapies (ecDTx) to inhibit those targets. Its main ecDTx candidate under development, BBI-940, is a novel, oral, selective degrader that has demonstrated potent anti-tumor activity across a range of cancer cell lines and mouse xenograft models, including single-agent tumor regressions.

Previous Close:

$2.60

Open:

$2.61

24h Volume:

255.08K

Relative Volume:

1.04

Market Cap:

$60.51M

Revenue:

Net Income/Loss:

$-55.99M

P/E Ratio:

-1.0634

EPS:

-2.5013

Net Cash Flow:

$-47.60M

1W Performance:

-5.34%

1M Performance:

-9.52%

6M Performance:

+135.40%

1Y Performance:

+135.40%

1-Day Range:

$2.59

$2.67

1-Week Range:

$2.59

$2.93

52-Week Range:

$0.9612

$3.1636

Boundless Bio Inc Stock (BOLD) Company Profile

Name

Boundless Bio Inc

Sector

Healthcare (1067)

Industry

Biotechnology (595)

Phone

(858) 766-9912

Address

10955 ALEXANDRIA WAY, SAN DIEGO

Employee

Twitter

Next Earnings Date

2026-11-04

Latest SEC Filings

BOLD's Discussions on Twitter

Compare BOLD vs VRTX, REGN, MRNA, ARGX, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
BOLD Boundless Bio Inc	2.66	60.51M	0	-55.99M	-47.60M	-2.5013
VRTX Vertex Pharmaceuticals Inc	526.19	133.37B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	788.04	81.13B	14.92B	4.42B	3.79B	41.04
MRNA Moderna Inc	198.88	79.40B	2.23B	-3.19B	-1.60B	-8.1462
ARGX Argen X Se Adr	959.49	60.03B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	204.97	43.93B	742.00K	-1.37B	-1.07B	-7.0731

Boundless Bio Inc Stock (BOLD) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jun-02-25	Initiated	H.C. Wainwright	Buy
May-28-25	Downgrade	Leerink Partners	Outperform → Market Perform
Dec-13-24	Downgrade	Guggenheim	Buy → Neutral
Apr-22-24	Initiated	Guggenheim	Buy
Apr-22-24	Initiated	Leerink Partners	Outperform
Apr-22-24	Initiated	Piper Sandler	Overweight

View All

Boundless Bio Inc Stock (BOLD) Latest News

Sep 21, 2026

Boundless Bio Inc. Share PriceBOLD, RNS News, Articles, Quotes, & Charts (NASDAQ:BOLD) - Proactive financial news

Sep 21, 2026

Sep 15, 2026

Serapha Bio Appoints Kenneth T. Mills as Chief Executive Officer and Names Senior Leadership Team to Advance Potential Best-in-Class in vivo Base Editing Program for Alpha-1 Antitrypsin Deficiency - manilatimes.net

Sep 15, 2026

Sep 12, 2026

Why Did BOLD, BLZE, QNT Stocks Surge To 52-Week Highs Today - stocktwits.com

Sep 12, 2026

Sep 03, 2026

TANG KEVIN C Trims Boundless Bio Inc (BOLD) Stake Amid Volatile Trading - GuruFocus

Sep 03, 2026

Boundless Bio (BOLD) Q2 2026 Earnings: Wider-than-Expected Loss of $1.06 per Share Pressures the Stock - dars.gov.et

Sep 03, 2026

Sep 01, 2026

BOLD Q2 2026 Earnings: Wider-than-Expected $1.06 Per Share Loss Reflects Clinical-Stage InvestmentEPS Revision Trend - careplusvn.com

Sep 01, 2026

Aug 31, 2026

Boundless Bio (NASDAQ: BOLD) Updates Serapha Merger with 19.99% Ownership Cap and Revised Voting Rules - kalkinemedia.com

Aug 31, 2026

Aug 28, 2026

Boundless Bio Amends Merger Agreement with Serapha Bio - TipRanks

Aug 28, 2026

Boundless Bio (NASDAQ: BOLD) adds $0.00001 warrants to cap ownership in Serapha deal - Stock Titan

Aug 28, 2026

Kevin Tang group trims Boundless Bio (BOLD) stake, returns profit - Stock Titan

Aug 28, 2026

2,426,857 Boundless Bio (NASDAQ: BOLD) shares held by Zachary Hornby - stocktitan.net

Aug 28, 2026

Aug 25, 2026

Boundless (BOLD) Results Check: EPS Falls Short of Its Estimate; Investor Response: The Stock Ends Down 1.33% in the Latest ReadingEarnings Miss Streak - dars.gov.et

Aug 25, 2026

Aug 24, 2026

Boundless (BOLD) Financial Update: Profit Per Share Falls Below Its Benchmark in the Reported Period - careplusvn.com

Aug 24, 2026

Aug 20, 2026

Boundless (BOLD) Session: Climbs 1.40% to $2.90 in the Current Update; Trading Range: Price Remains Between $2.75 Support and $3.04 Resistance on the DayFactor Timing - vinanet.vn

Aug 20, 2026

Boundless (BOLD) Results Versus Estimates: Profit Per Share Falls Below Its Benchmark in the Available Record; Shares Show Limited Movement under the Current SnapshotFiscal Year Earnings - vinanet.vn

Aug 20, 2026

Aug 14, 2026

Boundless Bio (BOLD): ADAR1 Capital discloses 8.8% beneficial ownership stake - Stock Titan

Aug 14, 2026

Boundless Bio (BOLD): Citadel entities and Ken Griffin report 0.6% ownership - Stock Titan

Aug 14, 2026

Aug 13, 2026

Boundless Bio (BOLD) Edges Up to $2.79 as Stock Holds Tight Trading RangeTriple Bottom - Vinanet

Aug 13, 2026

Aug 07, 2026

Boundless Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com

Aug 07, 2026